The primary objective of the Monoclonal Antibody CMV Retinitis Trial is to compare the safety and efficacy of human anti-CMV monoclonal antibody (MSL 109) plus active primary treatment versus matched placebo plus active primary treatment, for both newly diagnosed and relapsed CMV retinitis patients with AIDS.
Showing the most recent 10 out of 869 publications